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ABSTRACT 
BACKGROUND: To evaluate the efficacy of deep inspirational breath 
hold technique and its dosimetric advantages over free breathing technique 
in cardiac (heart and LAD) and ipsilateral lung sparing in left sided 
postmastectomy field in field conformal radiotherapy. DIBH is highly 
reproducible which arrest the respiratory motion provides clinical and 
dosimetric benefits over free breathing (FB). 
MATERIALS AND METHODS: Nineteen left sided post mastectomy 
patients were immobilized using breast board with both the arms positioned 
above the head. For all the patents, two sets of planning CT images were 
acquired using Biograph true point HD CT scanner with the same setup, 
one with FB and the other during DIBH by tracking the respiratory cycles 
using Varian real time position management (RPM) system. The target 
(chest-wall and supraclavicular region), OARs (ipsilateral lung, 
contralateral lung, heart, LAD and contralateral breast) and other organs at 
interests were delineated as per the RTOG contouring guidelines. The 
single isocenter conformal field in field treatment plans were generated in 
the Eclipse treatment planning system in both FB and DIBH images and 
doses to the target and OARs were compared. The standard fractionation 
regimen of 50 Gy in 25 fractions over a period of 5 weeks was used for all 
the patients in this study.  
 
RESULTS AND DISCUSSION: The target coverage parameters (V95, 
V105, V107 and Dmean) were found to be 97.8 ±0.9%, 6.1 ±3.4%, 0.2 
±0.3% and 101.9 ±0.5% respectively in FB plans and 98.1 ±0.8%, 6.1 
3.2%, 0.2 ±0.3%, 101.9 ±0.4% in DIBH plans respectively.  The plan 
quality indices CI and HI also showed 1.3 ±0.2 and 0.1 for FB plans and 
1.2 ±0.3 and 0.1 respectively for DIBH plans. There was significant 
reduction in dose to heart in the DIBH plans compared to FB plans with p 
value nearly 0 for V5, V10, V25, V30 and Dmean dosimetric parameters.
  The ipsilateral lung dose difference between FB and DIBH showed 
statistically significant p values and the difference in mean doses were 
found to be 7%, 15.7%, 11.8% and 10.7% in V5, V20, V30 and Dmean 
respectively.  Significant reduction in dose to LAD in the DIBH plans 
compared to FB.  
CONCLUSIONS:  DIBH resulted in significant reduction in doses to the 
Heart, LAD and Lungs as with this technique there was an increase in 
distance between target and the OARs. With appropriate patient selection 
and adequate training, DIBH technique for radiotherapy to the chest is 
acceptable and achievable and therefore should be considered for all 
suitable patients as this could result in less radiotherapy related 
complications. However this technique is time consuming as the set up is 
complex, results in increased time for treatment delivery, needs patient co-
operation and technical expertise. 
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1. INTRODUCTION 
 
1 INTRODUCTION 
 Among various diseases, cancer has significant mortality rates 
globally and has become one of the life threatening disease (1). Though 
several technological advancements have been incorporated in the diagnosis 
and treatment for most of the diseases, cancer is still a challenging disease. 
As per the data reported by Parkin, there were 10 million new cases, 6 
million cancer cause deaths and 22 million people living or diagnosed with 
cancer in 2000 worldwide (2). Among several types of cancer reported in 
Indian population such as cancers of skin, brain, lungs, rectum, stomach, 
bladder, prostate, liver, oesophagus and mouth etc., cervix and breast 
cancers are common type and principle cause of death among women 
(1,3,4). There are many factors associated with incidence rates of breast 
cancers such as genetics, mutation, hormonal, environment, lifestyle and 
dietary habits etc., (3,5–7). 
 There have been several advancements in the diagnosis and 
treatment of cancer over the past two decades. Management of breast 
cancer has also witnessed changes from surgical intervention alone to 
multimodality treatments including chemotherapy, hormonal and targeted 
therapy and radiotherapy owing to the better understanding of the biology 
and molecular characteristics.  
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           Radiotherapy in breast cancer has progressed from the use of 
conventional to conformal treatment techniques. Ever since its introduction 
into the management of breast cancer, radiotherapy has become an effective 
adjuvant treatment in achieving superior local control and also overall 
survival (8,9). However, there has been a risk of long term complications 
causing morbidity and mortality due to dose received by the underlying 
organs such as lungs and heart. Several studies have reported the correlation 
between the doses received by the heart and its effect in developing cardiac 
complications in the long term (10–12). There are studies which have 
reported that the cardiac toxicity was greater while delivering radiation 
therapy to the left sided breast cancer than the right (13–15). Hence efforts 
have been made in the planning techniques to decrease the doses to the 
heart and lungs without compromising on the target coverage. However, 
movement of chest wall due to breathing also accounts for variations in the 
doses delivered to the target and the OARs. Hence various methods have 
been developed to minimise this effect by using tumour tracking and deep 
inspirational breath hold (DIBH) while delivering radiation. In our study, 
we have done a dosimetric evaluation of DIBH technique in comparison 
with the free breathing to quantify the difference in the doses received by 
the OARs (heart, LAD and lungs) while delivering radiation to the left 
sided chest wall and supraclavicular region.  
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2. LITERATURE REVIEW 
2.1  EPIDEMIOLOGY OF BREAST CANCER 
According to GLOBOCAN 2012, an estimated 14.1 million new 
cancer cases and 8.2 million cancer-related deaths occurred in 2012, 
compared with 12.7 million and 7.6 million, respectively in 2008 (16). 
Owing to the considerable geographic changes in the incidence of cancers, 
breast cancer is common in developed countries than developing countries 
(4). According to world health organization (WHO), more than 1.2 million 
people are diagnosed with breast cancer worldwide every year, reported in 
the year of 2013 (6,17). Parkin reported breast cancer of about 1.05 million 
cases in the beginning of the last decade (2). The incidence and mortality of 
breast cancer has been increased by 20% and 14% respectively since the 
2008 estimates. In fact, 1.7 million (i.e. 11.9% of total) women were 
diagnosed with breast cancer and it represents one in four of all cancers in 
women worldwide. Moreover, the incidence of breast cancer is rapidly 
increasing in India which was reported in the recent publication on  
Epidemiological correlates of breast cancer by Babu et al (5). The following 
are the details reported by international agency for research on cancer 
(IARC) (figure 1), WHO in 2014 (18). 
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Incidence is the absolute 
number of new cases arising in a 
given period (per year) in a 
specified population (per 100,000).  
 
Figure 1 (A) Incidence of Cancer 
 
Figure 1 (B) Cancer Incidence by Country 
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Mortality is the absolute number 
of deaths occurring in a given 
period or per year in a specified 
population (per 100,000).  
 
 Figure 1 (C) Cancer Mortality  
 
 
Figure 1 (D) Cancer Mortality by Country 
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The breast cancer was showed as most prevalent cancer by country 
among females, reported by the IARC, world cancer factsheet, WHO is 
shown below,  
 
 
 
 
 
Figure 1 (E) Breast Cancer by Country 
 
 
 
 
 7 
2.2  HISTORICAL BACKGROUND OF THERAPY  
 Breast cancer was described as early as 3000 BC by the Egyptians. 
Subsequently Greek and Roman physicians have written various articles 
about treatment of breast cancer (19). The management of breast cancer has 
changed from single modality (i.e. surgery) to multimodality which 
includes surgery along with chemotherapy and radiotherapy. Radiotherapy 
has been introduced in the treatment of breast cancer in the twentieth 
century when surgery for breast cancer had reached its limits and the 
efficacy of radical surgeries was re-evaluated by physicians for several 
reasons like inability to cure breast cancer by surgery alone, morbidity of 
radical surgery, combined modality like surgery and postoperative 
radiotherapy resulting in similar local control as radical surgery with less 
morbidity, introduction of chemotherapy leading to survival advantage, 
better understanding of biology of breast cancer and usage of variety of 
hormonal agents etc. In 1948, Robert Mc Whirter was the first person to 
report the benefit of radiotherapy in the treatment of nodal disease in breast 
cancer (19). Radiotherapy for breast cancer has progressed from the usage 
of kilovoltage superficial x-rays, orthovoltage to Megavoltage beams over 
time. These technological advancements have lead to a better local control 
by delivering higher doses to the target volume (chest wall and nodal 
regions). However, they have lead to a higher risk of developing long term 
morbidity and mortality due to cardiac and lung complications in view of 
the doses received by them (20). This has lead to further improvement in 
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radiotherapy planning and dose delivery with high precision radiotherapy 
techniques. 
 
2.3  TREATMENT MODALITIES FOR BREAST 
CANCER 
 Treatment of breast cancer is multimodal and depends on several 
factors including the stage at presentation, patient related factors (age, 
patient preferences, general conditions etc.,), availability of services, 
physician expertise and socioeconomic factors. The various treatment 
modalities for breast cancer treatment are surgery, chemotherapy, 
radiotherapy, hormonal therapy and biological therapy.  
 
2.3.1 ROLE OF SURGERY  
 Surgery is the main modality of treatment in breast cancer (21) 
which could be mastectomy or breast conservation surgery. In recent years, 
there is a paradigm shift from radical surgery to less invasive procedures 
like breast conservation surgeries and sentinel node biopsy, which are 
evolving as the standard of care (22). Most common type of surgery 
practiced in India for breast cancer is modified radical mastectomy due to 
various factors. These include, tumour factors (locally advanced nature of 
disease at presentation), patient factors [concern about disease free survival 
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than conservation of breast, finances - breast conservative surgery is 
relatively expensive than mastectomy), poor adherence to follow up 
regimes], physician factors (surgical expertise and availability of recourses 
for surgery) and access to radiotherapy equipment.  
 
2.3.2 ROLE OF CHEMOTHERAPY 
 The goal of chemotherapy is to downstage the tumour when used in 
neoadjuvant setting and to decrease the chances of recurrence by 
eradicating micro-metastatic deposits. In addition, chemotherapy improves 
breast cancer outcome by preventing distant metastasis (23). Haagensen and 
Stout showed that there is  need for other treatment modalities along with 
surgery for locally advanced breast cancer (LABC) from the outcome of 
clinical results of 74 patients who underwent radical mastectomy (24).  
 The radical mastectomy alone was not curative and incorporation of 
systemic chemotherapy along with surgery and radiotherapy improves 
overall survival and recurrence control (24–26). The similar outcome of 
induction chemotherapy results of National Surgical Adjuvant Breast 
Project (NSABP) for preoperative and postoperative breast cancers 
highlighted the breast conserving therapy (26). The substantial reduction of 
recurrence risk and significant proportional reduction in mortality rate 
among women (aged under 50 and those aged 50 to 69) showed absolute 
benefits of adjuvant chemotherapy (25).  
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2.3.3 ROLE OF RADIATION THERAPY  
 Radiotherapy (RT) had been shown to be effective in treating breast 
cancer in the early twentieth century. The rationale for postmastectomy 
radiation is  prevention of  local-regional recurrence (27). Findings of the 
2005 Early Breast Cancer Trialists Group (EBCTCG) meta-analysis also 
showed the impact of improved local control on overall survival and 
showed that radiation therapy after breast conservation improved five year 
local control rates and also overall survival (28). In 1977, the Danish Breast 
Cancer Cooperative Group (DBCCG) suggested national guidelines for the 
first time regarding adjuvant radiotherapy for breast cancer (29,30).  
 The benefit of postmastectomy radiotherapy was first demonstrated 
by three randomized trials done between 1997 and 1999 in which patients 
who received adjuvant postmastectomy radiotherapy had statistically 
significant survival benefit when compared to those who did not receive the 
same (9,31). There would be a risk of local recurrence even after 
postmastectomy and various trials and metaanalysis have proven the 
advantage of adjuvant radiation in terms of reducing local recurrences and 
long term mortality due to breast cancer (9,28,31–33).  
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2.4  DIFFERENT TECHNIQUES OF EXTERNAL BEAM 
RADIATION THERAPY FOR BREAST CANCER 
 External Beam radiotherapy is grossly includes two types – 
Conventional and Conformal. The two dimensional Conventional 
radiotherapy (2DRT) makes use of regularly shaped, two to four equally 
weighted tangential beams with simple arrangements while conformal 
radiotherapy such as 3DCRT, IMRT (forward and inverse planning IMRT), 
IGRT, SBRT, Tomotherapy, volumetric arc therapy uses irregularly shaped, 
unequally weighted, multiple beam arrangements .  
 
2.4.1 TWO DIMENTIONAL CONVENTIONAL 
RADIATION THERAPY  
The conventional (2D) treatment planning consists of standardized 
treatment techniques making use of an x-ray simulator which simulates the 
functions and motions of the treatment unit and a 2D computer planning 
system which is used for dose calculation and to generate a dose 
distribution.  In order to reduce the doses to the heart and lungs in  
conventional radiotherapy, parallel opposed tangential beams are used. 
More often the half beam blocked tangential beam technique is used. The 
patient is immobilised on a breast board and aligned by the help of two 
lateral lasers and an anterior laser. The field borders are fixed according to 
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the anatomical landmarks and adding margin to the field to account for 
penumbra as well as setup uncertainties. Additional margin to the field is 
given anteriorly to account for breathing movement.  
In addition, the parameters such as central lung distance (CLD), 
maximum lung distance (MLD), average lung distance (ALD) and maximal 
heart distance (MHD) are also considered and the field borders are adjusted 
accordingly to ensure better target coverage and also to reduce the doses to 
the lungs and heart which will predict the probability of radiation induced 
pneumonitis and cardiac toxicity (34,35).  The figure 2 shows the CLD and 
MHD in a simulator film. 
 
 
 
 
 
 
 
 
Figure 2 Simulator Film with CLD and MHD Marking 
(Courtesy: Practical Radiotherapy Planning by Jane Dobbs).  
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2D planning system generates dose distribution only in a single or 
few planes which could lead to treatment inaccuracy and thereby limiting 
its usage. The primary obstacles to achieve the maximum possible 
therapeutic advantage when the patient is being treated with conventional 
radiotherapy are the following: 
 Uncertainties in the actual spatial extent of the target 
 Inadequate knowledge of the special location and accurate shapes of 
OARs  
 Unavailability of appropriate devices  for conformal treatment 
planning and delivery  
 limitations of computing desirable isodose distribution with the 
existing methods (36) 
The advent of computed tomography (CT) and  magnetic resonance 
imaging (MRI) and its incorporation in the planning and treatment has lead 
to better localisation of the tumour and has led to the development of 
conformal radiotherapy. 
 
2.4.2 THREE DIMENTIONAL CONFORMAL RADIATION 
THERAPY  
 Three-dimensional conformal radiation therapy (3DCRT) is a 
technique where irregularly shaped beams are used in different projections 
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to match the size and shape of the tumour. This can be achieved by 
multileaf collimators which are independently moving banks of leaves 
attached in the treatment head of a linear accelerator (37). In conventional 
radiotherapy, the height and width of the tumour are matched with regularly 
shaped square or rectangular fields in which there is a chance of more 
healthy tissue being exposed to radiation. Advances in imaging technology 
such as CT, MRI, PET (Positron Emission Tomography) and SPECT 
(Single photon emission Computer tomography) have made it possible to 
locate and treat the tumour more precisely. CT images are used in 
computerized treatment planning systems (TPS) for dose calculation (38) 
which provide three dimensional anatomical details and tissue density 
information as arbitrary number (correspond to linear attenuation value) 
called Hounsfield units. 3DCRT uses the three dimensional projection 
images of the CT to focus precisely on the target with different gantry 
direction, while avoiding OARs and healthy surrounding tissue. Figure 3 
shows the irregularly shaped MLC, beams eye view of target and OARs and 
dose distribution on CT image of 3D breast radiotherapy.  
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Figure 3 (A) Irregularly shaped BEV of the tangent beam 
 
 
 
 
 
 
 
Figure 3 (B) Isodose Distribution of 3DCRT Plan with Tangential 
Beams 
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2.4.3 INTENSITY MODULATED RADIATION THERAPY  
 Intensity-modulated radiation therapy (IMRT) is an advanced form 
of 3DCRT. It uses sophisticated treatment planning software and hardware 
to vary the shape and intensity of radiation beam delivered to different parts 
of the patient body. IMRT is the most precise form of external beam 
radiation therapy and suitable treatment option for many sites such as head 
and neck, prostate cancer and breast cancer etc. IMRT permits treatment 
with rapidly varying intensity or fluence across fields that can be optimized 
to fit to the complex target volume defined by the physician, resulting in 
improved dose conformity and avoidance of critical structures (39,40). 
Several IMRT techniques were reported in radiotherapy in last two decades, 
differing in method of plan optimization and dose delivery (41). However, 
the MLC based IMRT techniques such as inverse planned IMRT (step and 
shoot or dynamic) and static or forward planned IMRT are widely used for 
treatment of breast radiotherapy. IMRT treatment offers fewer side effects 
than 3DCRT, but generally takes more time for planning and to deliver the 
desired dose. 
 
2.4.3.1 INVERSE PLANNED IMRT 
 In inverse planned IMRT, the physician designates patient 
specific dose constraints to the target, OARs and surrounding normal 
tissues in the optimization process as expected input (39). In this method, 
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the sophisticated computerized treatment planning software is used to 
develop an individualized plan to meet the target and OAR dose constraints 
by allowing various intensity levels of radiation beam with different gantry 
angles. This process is termed inverse treatment planning. Figure 4 shows 
the inverse planned IMRT dose distribution for left sided breast 
radiotherapy plan.  
 
Figure (4) Inverse Planned IMRT Dose Distribution for left 
sided breast cancer. 
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2.4.3.2 FIELD IN FIELD OR FORWARD PLANNED 
IMRT  
 Unlike inverse planned IMRT, Field in field (FiF) or forward 
planned IMRT has 2 or more lower weighted sub fields or segmented fields 
which is created from the primary fields to shield the high dose region and 
increase the dose at cold spots in the target (42). FiF treatment plans does 
not require a pre-treatment quality assurance like inverse planned IMRT 
(43). FiF plans allow homogeneous dose distribution across the target 
volume than 3DCRT (44) and inverse planned IMRT, resulting in 
significant reduction in hotspot (lower maximum dose) (105%, 107% and 
110%) and cold spot region within the target (higher minimal dose) (45–
47). Figure 5 shows the sub fields used to shield the high dose in a FiF plan. 
  
 19 
 
 
 
 
 
 
 
Figure 5 BEV of partially shielded sub-filed in FiF plan to block 
105% isodose (magenta coloured).  
2.5 EFFECT OF RESPIRATORY MOTION IN 
RADIATION THERAPY FOR BREAST 
 Respiratory, cardiac and gastrointestinal systems effect the 
movement of the target during radiotherapy among which respiratory 
motion has a significant effect on the intra and inter fractional delivery of 
radiotherapy to the chest or abdomen (48).  Respiratory motion also causes 
artefacts during image acquisition which leads to distortion of the tumour 
volume and incorrect spatial representation of the anatomical structures 
(49,50). Figure 6 A and B shows CT scan images of thoracic region 
(coronal view) of a patient during  free breathing and deep inspirational 
breath hold. 
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   (A)     (B)  
Figure 6 CT images (coronal view) of thoracic region of a patient 
during free breathing (A) and deep inspirational breath hold (B). 
Courtesy: Managing Respiratory Motion in Radiation Therapy, Keall 
P and Mageras G, AAPM TG 76 2004. 
 Hence efforts have been made to account for and counteract the 
same. The following methods/techniques were described for management 
of respiratory motion during radiotherapy (48,49).  
A. Respiratory gated techniques  
B.  Motion encompassing methods 
C. Respiration synchronized techniques 
D. Forced shallow breathing methods 
E. Breath hold techniques  
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A. RESPIRATORY GATED TECHNIQUES 
 Respiratory gating denotes the acquisition and delivery of radiation 
(during imaging and treatment) during a specific phase of the respiratory 
cycle, often referred as ‘Gate’. By monitoring the patient’s respiratory cycle 
using either external or internal signals (with infrared camera or fiducial 
markers), the width and position of the gate can be determined (49,51). The 
Varian Real-time Position Management (RPM) system is the only 
commercially available software used for respiratory gated therapy and the 
same has been used in our study. 
 
 
B. MOTION ENCOMPASSING METHODS 
 As there will be movement of the target and other structures due to 
breathing during delivery of radiation, estimation of the range of motion 
and the mean position of the target during imaging is important. The 
techniques available to include the range of tumour motion during imaging 
are, 
 
I. Slow CT 
II. Inhale and Exhale breath hold CT 
III. 4D CT  
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 Though these methods account for respiratory movement during 
imaging, there is a possibility of  increased radiation exposure to the patient 
if not performed well.(48, 51–54)  
  
C. RESPIRATION SYNCHRONIZED TECHNIQUES 
 Respiratory synchronized or real time tracking technique is one of 
the effective methods to dynamically accommodate respiratory motion by 
shifting or sweeping the beam in space to synchronize with normal 
respiratory cycle which make use of 100% duty cycle during dose delivery. 
This technique is less practised due to limited experience and technical 
expertise (49,56,57).  
  
D. FORCED SHALLOW BREATHING METHODS 
 This technique was developed by Lax and Blomgren at Karolinska 
Hospital in Stockholm, to reduce the magnitude of the intra fractional 
motion during SBRT of lung and liver tumours. A stereotactic body frame 
equipped with the pressure plate (this equipment commercially produces by 
Elekta medical systems) used in this technique to minimize the 
diaphragmatic excursions, there by controlling the gas exchange during free 
breathing. Though several groups were studied the accuracy and 
reproducibility of this equipment, Negoro et al reported the most 
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comprehensive method (58,59). This method is not in much practise for 
breast radiotherapy.  
 
E.  BREATH HOLD METHODS 
 There are three types of breath hold methods such as Active 
Breathing Control (ABC), Self-held breath-hold, Self-held breath-hold 
using an External Marker and Deep inspirational breath hold. 
 
I. ABC METHOD  
 ABC method was developed at William Beaumont Hospital and 
commercialized by Elekta, Inc. as the Active Breathing Coordinator (48). 
This method facilitates reproducible breath-hold technique in which the 
patient does not require to hold the breath with maximum inspiration 
capacity (60–62). Any pre-determined phase at active inspiration or along 
the free breathing cycle can be suspended by ABC apparatus. Figure 7 
shows the Elekta’s ABC system.   
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Figure 7 The Elekta’s ABC system. Courtesy: Managing Respiratory 
Motion in Radiation Therapy, Keall P and Mageras G, AAPM TG 76 
2004. 
 
 
II. SELF-HELD BREATH-HOLD 
 In self breath hold technique, the patient holds the breath at some 
point in the breathing cycle and the beam will be turned on when the patient 
holds the breath. It makes use of Customer Minor (CMNR) interlock circuit 
where the patient can turn off the beam. Deep inspiration or expiration has 
proven to be most reproducible positions than any other phase of respiration 
as per several studies. Further, deep inspirational breath hold has further 
advantage of increasing the lung volumes significantly (48,49,55,63). In our 
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study, we have compared the differences in lung volumes between FB CT 
and DIBH CT.  
 
III. SELF-HELD BREATH-HOLD USING AN EXTERNAL 
MARKER 
 In this technique, patients are instructed to hold their breath in 
specific phase respiratory cycle. There are two advantages in this technique 
such as Fastest dose delivery (~100 MU per 10 seconds breath hold using 
600 MU/min dose rate while same dose delivery would take 30 seconds in 
FB technique) and Constant observation (constantly monitor the patient’s 
respiratory cycle using a external fiducial marker which disable the beam if 
the patient fail to hold the breath in a specific phase of respiratory cycle) 
(48,49).  
IV. DEEP INSPIRATIONAL BREATH HOLD 
 DIBH is most reproducible and controlled breathing technique under 
supervision during treatment, originally developed for treatment of lung 
cancers to reduce the PTV margin (1 to 2 cm) there by increasing the dose 
escalation while maintaining the same normal tissue complication 
probability (NTCP) (51,64,65).  Studies proved that the heart moves away 
from the chest wall during DIBH. Remouchamps et al showed significant 
reduction in heart and lung doses by adapting the DIBH technique along 
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with ABC apparatus (66). Further, it showed as a more efficient and 
feasible technique to reduce the respiratory motion effectively and spare the 
normal tissue by increasing the lung volume (51) and also reduce the late 
cardiac toxicities associated with radiotherapy (67). The reproducibility of 
DIBH was reported by Hanley et al in which the average intra and inter 
breath hold deviation of 1 mm and 2.5 mm respectively (ranging from 0.5 
mm to 4.9 mm) for lung-diaphragm boundary position while 26.4 mm was 
the deviation in normal breathing for the same (64). In order to reduce the 
risk of cardiovascular morbidity and mortality, the goal of reduction of 
dose-volume irradiation to the heart has become common in breast 
radiotherapy. Ha Yoon Lee et al reported the feasibility of DIBH in daily 
practice and potential reduction in radiation to the heart and LAD for left 
sided breast cancer (60). Similar study was also reported by Hayden et al in 
which he showed significant reduction in dose to heart and LAD in DIBH 
technique than FB (68). Feasibility and setup variability of fluoroscopy 
guided DIBH irradiation for left sided breast cancer was reported by Borst 
et al. He showed lower heart dose in comparison with FB and small setup 
variability (which did not affect the dose delivery to the chest wall) (69). 
Latty et al evaluated several DIBH techniques and showed the need for an 
optimum protocol for patient training and treatment evaluation, in order to 
achieve the accurate treatment delivery. The reproducible state of DIBH is 
beneficial to patients undergoing breast and thoracic radiotherapy; it 
significantly reduces respiratory motion and protects critical normal tissues. 
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Several methods for implementing DIBH have been developed and are 
described in this report. All the methods require patient compliance, active 
participation and, often, extra therapist participation. 
 
2.6 OARs IN POST-MASTECTOMY RADIOTHERAPY 
AND RADIATION INDUCED SIDE EFFECTS 
A. LUNGS 
 Radiation induced lung disease (RILD) is a common complication of 
radiotherapy to the chest wall. It includes acute and late phases which 
correspond to radiation induced pneumonitis and radiation fibrosis 
respectively, as shown in figure 8. The risk of developing RILD depends on 
various factors like the total dose of radiation given (rare below 20 Gy, 
common above 40 Gy), fractionation, prior chemotherapy (Actinomycin D, 
Adriamycin, Bleomycin) (70). Table 1 shows the RTOG Acute Radiation 
Morbidity Scoring Criteria for lung.  
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Table 1 Acute Radiation Morbidity Scoring Criteria for lung - RTOG 
Grade Signs and Symptoms 
0 No change 
1 
Mild symptoms of dry cough or dyspnoea on 
exertion 
2 
Persistent cough requiring narcotic, antitussive 
agents/ dyspnoea with minimal effort but not at rest 
3 
Severe cough unresponsive to narcotic antitussive 
agent or dyspnoea at rest/ clinical or radiologic 
evidence of acute pneumonitis/ intermittent oxygen 
or steroids may be required 
4 
Severe respiratory insufficiency/ continuous oxygen 
or assisted ventilation 
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                       (A)            (B) 
 
 
 Figure 8 Radiation induced pneumonitis (A) and fibrosis (B) 
 
 
 
B. HEART 
 Postmastectomy radiotherapy to the left chest wall invariably leads 
to exposure to the heart to radiation and hence the occurrence of long term 
complications. Even though the doses received by the heart could be 
significantly reduced due to modern radiotherapy techniques, several 
studies have shown that the average dose received by the heart is about 1 to 
5 Gy. Exposure of this doses can cause ischemic heart disease, though the 
risk of development is uncertain and depends on presence of other cardiac 
risk factors (71). Table 2 shows the RTOG grading of cardiac morbidity due 
to radiation. The spectrum of radiation induced cardiac damage can range 
from Asymptomatic Coronary artery disease to sudden death (Table 3).  
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Table 2 Acute Radiation Morbidity Scoring Criteria for Heart - RTOG 
Grade Signs and Symptoms 
0 No change over baseline 
1 
Asymptomatic but objective evidence of EKG changes or pericardial 
abnormalities without evidence of other heart disease 
2 
Symptomatic with EKG changes and radiologic findings of congestive 
heart failure or pericardial disease/ no specific treatment required 
3 
Congestive heart failure, angina pectoris, pericardial disease responding to 
therapy 
4 
Congestive heart failure, angina pectoris, pericardial disease, arrhythmias 
not responsive to non-surgical measures 
 
Table 3 The spectrum of radiation induced heart disease 
 
Courtesy: Radiation Induced Heart Disease, A Clinical Update Yusuf 
et al, Cardiology Research and Practice, 2011. 
Radiation-
induced 
atherosclerosis 
Pericardial disease 
Myocardial and 
Endocardial 
disease 
Conduction 
disturbances 
Valvular 
disease 
Symptomatic 
Acute pericarditis 
Pancarditis RBBB 
- 
Delayed pericarditis 
Asymptomatic 
Pericardial effusion 
Cardiomyopathy 
Atrioventricular 
nodal block Constrictive 
pericarditis 
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C. LEFT ANTERIOR DESCENDING ARTERY (LAD) 
          LAD is one of the major coronary arteries supplying the 
anterior part of heart especially the ventricles and is the most 
common artery involved while delivering radiation to the left chest 
wall and the nodal regions as it is mostly received by the anterior 
part of the heart where the LAD is located. Doses received by the 
LAD are directly proportional to the risk of development of radiation 
induced ischemic heart disease hence studies have been done to 
quantify the doses received by LAD and its impact on development 
of cardiac morbidity.(72,73) 
 
D. CONTRALATERAL BREAST  
   In the patients with breast cancer, there is a risk of development of 
malignancy in contralateral breast owing to various causes like 
genetic predisposition, tumour related factors like the histology, 
receptor status etc., The incidence has significantly decreased which 
can be attributed to the effective adjuvant therapies. However there 
exists a slight risk of development of second malignancy in the 
contralateral breast after receiving radiation for breast cancer. 
Considering a 55 year old healthy lady and a lady of the same age 
who is a breast cancer survivor, the risk of developing breast cancer 
would be 2.5% and 10 – 15 % respectively. But only a small percent 
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of this is attributed to the treatment and the risk after radiotherapy is 
mostly due to the scattered doses.(74,75) 
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3. AIMS AND OBJECIVES 
AIM 
 To evaluate the efficacy of deep inspirational breath hold technique and its 
dosimetric advantages over free breathing technique in cardiac (heart and LAD) 
and ipsilateral lung sparing in left sided postmastectomy field in field conformal 
radiotherapy. 
OBJECTIVES 
 To study the effect of deep inspirational breath hold on doses to the Heart, 
Left anterior descending coronary artery (LAD) and Lung for conformal 
postmastectomy radiotherapy to the chest wall in left sided carcinoma breast 
patients.  
 To compare the doses received by organs at risk the heart, LAD and lung 
during radiotherapy for post mastectomy left sided carcinoma breast during free 
breathing versus deep inspirational breath hold. 
 
 SECONDARY OBJECTIVE 
 To assess the feasibility of deep inspirational breath hold CT scan. 
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NULL HYPOTHESIS 
 There is no significant difference in doses received by the heart, LAD and 
lung in free breathing versus deep inspirational breath hold. 
RELEVANCE OF THIS STUDY 
1. Documentation and quantifying the influence of deep inspirational 
breath hold on doses received by the heart and LAD  
2. It will aid in decision making, regarding treating the patients in deep 
inspirational breath hold in order to reduce the doses of radiation to 
the organs at risk without compromising on the dose to the target. 
INCLUSION CRITERIA 
1. Women with left sided breast cancer who require postmastectomy 
radiotherapy to chest wall and supraclavicular region 
2. Patients who consent for undergoing CT scan in deep inspirational 
breath hold in the same setting and use of images for study purpose 
 
EXCLUSION CRITERIA 
1. Persons who cannot hold breath due to any reason 
2. Patients who had primary or secondary flap reconstruction 
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SETUP UNCERTAINTY FACTORS  
1.  Height 
2.  Weight 
3.  Body mass index 
 
 
PATIENT EVALUATION PARAMETERS 
 
 
 
S.No Variables Parameters  
Threshold / 
Limits/Sources 
1 Age 
< 40 years Lower Limit 
41 to 55 years Normal  
> 55 years Upper Limit 
2 BMI 
< 19 kg/m2 Under Weight 
19 to 25 kg/m2 Average 
25 to 30 kg/m2 Over weight  
> 30 kg/m2  Obese 
3 Lung Volume cubic centimetres 
 
- 
 
4 
Heart distance 
from the CW  
centimetres - 
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4.   MATERIALS AND METHODS 
DIAGRAMMATIC ALGORITHM OF THE STUDY  
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 The patients undergoing post mastectomy radiotherapy for left sided 
breast cancer were recruited for this study after signing the consent form. 
Baseline ECHO and Pulmonary function tests were done. All the patients 
were well explained about the DIBH technique. They were trained 
regarding the same and were instructed to practice it for atleast a period of 
three days before undergoing planning CT scan.  
 
4.1 CALIBRATION OF TRACKING SYSTEM 
Calibration of infrared (IR) camera system (Varian medical system, 
USA) was performed prior to acquisition of the images. Figure 9 shows the 
six marker neon localizer box, video assisted goggles and the calibration 
setup of the IR camera,. Initially, the localizer box was kept on the 
calibration test tool at isocenter position using lasers. It was followed by a 
10 step calibration procedure using Varian RPM software by placing 
localizer box at various positions on the test tool with fixed table vertical 
position (ideally at 200) and three different longitudinal position to account 
for the coordinates of the various table position during CT scan. For each 
patient, the calibration check was performed to verify the shift in x, y and z 
coordinates of the table (calibration validity) measured by the IR camera 
system. In this study, maximum deviation of ± 3 mm from the calibration 
coordinates was accepted. 
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     (A) 
 
 
 
 
 
 
 
 
 
 
     (B) 
Figure 9 (A) The six marker neon localizer box with cross hairs 
and the goggle used in this study (B) Calibration setup with fixed couch 
vertical position using lasers.  
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4.2  IMAGE ACQUISITION 
The planning CT images of the patients were acquired using 
Biograph true point HD CT scanner (Siemens, Germany). The patients were 
immobilized on a breast board with both arms abducted above the head. 
The planning CT images were acquired with 3 mm slice thickness from 
level of second cervical vertebra till the adrenals with field of view of 700 
mm (maximum FOV) and the standard thorax imaging parameters. For all 
the patents, two sets of planning CT images were acquired with the same 
setup, one during the normal breathing cycle (free breathing) and the other 
one during deep inspirational breath hold.  
 
4.3 TRACKING OF RESPIRATORY CYCLE 
After acquiring the images of the patient during free breathing, the 
respiratory cycle of the patient was tracked by placing the localizer box on 
the patient in the treatment setup position. Initially, the baseline respiratory 
cycle was recorded. Following this, the patient was instructed through audio 
system to hold the breath in deep inspiration for 15 to 20 seconds to record 
the respiratory phase in DIBH. Planning CT images were acquired after two 
to three successive trials done to verify the patient’s ability to perform 
DIBH. The same acquisition parameter was used while acquiring the DIBH 
images. 
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4.4 TREATMENT PLANNING  
The planning CT images were transferred to the Eclipse treatment 
planning system (TPS) (Varian Medical Systems, USA). The free breathing 
and deep inspiration breath hold CT image sets were named as CT FB and 
CT DIBH respectively. The target (chest-wall and supraclavicular region), 
OARs (ipsilateral lung, contralateral lung, heart, LAD and contralateral 
breast) and other organs such as esophagus, liver, thyroid and spine were 
delineated as per the RTOG contouring guidelines (Breast Cancer Atlas for 
Radiation Therapy Planning, Radiation Therapy Oncology Group). The 
single isocenter 3D conformal field in field (FiF) treatment plans were 
generated in the Eclipse TPS for both FB and DIBH images. Two 
conformal tangent beams for the chest wall and one direct anterior beam for 
supraclavicular region were added and the FiFs were created in the 
tangential fields. 6 MV and 15 MV photon beams were used for the chest 
wall and supraclavicular regions respectively. The standard fractionation 
regimen of 50 Gy in 25 fractions over a period of 5 weeks was used for all 
the patients in this study.  
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PLAN EVALUATION PARAMETERS 
S. No Structures Dosimetric Parameters 
Cumulative 
DVH Mode 
1 
Target 
(CTV plus SC) 
V95%, V105%, V107%, 
D98%, D2%, Dmin, Dmax  
and Dmean 
(Dose –Volume  
coverage) 
Relative 
2 
Target 
(CTV plus SC) 
HI and CI 
(Plan Quality Paramaters) 
Relative 
3 Ipsilateral Lung 
V5 Gy, V20 Gy, V30 Gy 
and Dmean 
Absolute 
4 Combined Lung 
V5 Gy, V20 Gy, V30 Gy 
and Dmean 
Absolute 
5 
Contralateral 
Lung 
V5 Gy and Dmean Absolute 
6 Heart 
V5 Gy, V25 Gy, V30 Gy 
and Dmean 
Absolute 
7 LAD 
V5 Gy, V10 Gy, V25 Gy 
Dmean 
Absolute 
8 
Contralateral 
Breast 
V5 Gy and Dmean Absolute 
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4.5  DOSIMETRIC EVALUATION 
 I. TARGET  
All the plans were evaluated by analyzing the dose distribution and 
dose volume histogram (DVH). For target volumes (CW and SC), the 
dosimetric parameters such as V95, V105, V107, Dmean and Dmax were 
obtained from the cumulative DVH and the comparison was made between 
the DVH of the FB and DIBH plans using Eclipse TPS.  
 
where, the parameters, 
V95 corresponds to the volume of target receiving 95% of the 
prescription dose, 
V105 corresponds to the volume of target receiving 105% of the 
prescription dose, 
V107 corresponds to the volume of target receiving 107% of the 
prescription dose 
Dmean and Dmax are the mean and maximum dose received by the 
target volume respectively.  
 
Additionally, the homogeneity and conformity indices (HI and CI) of 
the FB and DIBH plans were determined and compared. The homogeneity 
index was calculated by the following formula recommended by the 
international commission of radiation units and measures (ICRU report 83). 
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  HI = D2 – D98 / Dmean 
  
where,  
 D98 correspond to the absorbed dose received by 98% of target 
volume and 
 D2 correspond to the absorbed dose received by 2% of target volume  
 
In ICRU report 83, the dosimetric parameters Dmin and Dmax are 
redefined as D98 and D2 which correspond to minimum and maximum 
absorbed dose or isodose received by the target volume respectively. 
 
The CI was calculated by the following formula, 
 
  CI = VI / TV 
where,  
VI represents the volume of reference or prescription isodose in cc 
and  
TV represents the volume of target in cc  
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 II. OARs 
A. IPSILATERAL LUNG AND COMBINED LUNG 
For each patient, the V5, V20, V30 and Dmean of ipsilateral and 
combined lung volumes of the FB and DIBH treatment plans were 
analyzed and compared.  
Where, the parameters, 
V5 corresponds to the volume of lung receiving 5% of the 
prescription  dose, 
V20 corresponds to the volume of lung receiving 20% of the 
prescription  dose, and 
V30 corresponds to the volume of lung receiving 30% of the 
prescription  dose. 
 
B. CONTRALATERAL LUNG 
For contralateral lung, the V5 and Dmean from cumulative DVH 
of FB and DIBH plans were analyzed and compared. 
C. HEART 
Of all the OARs, heart and the coronary vessels are the most 
important critical structures owing to the long term complications. 
For each patient, V5, V10, V25, V30, Dmean were analysed and 
compared. 
Where, 
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V10 corresponds to the volume of heart receiving 10% of the 
prescription dose, 
V25 corresponds to the volume of heart receiving 25% of the 
prescription dose, 
V5 and Dmean as stated above.  
 
D. LAD 
The volume of LAD receiving 5 Gy, 10 Gy, 25 Gy and the mean 
doses (V5, V10, V25 and Dmean) were analyzed.  
 
E. CONTRALATERAL BREAST 
For contralateral breast volume, V5, Dmean and Dmax of FB and 
DIBH plans were compared.  
Dmax corresponds to the maximum point dose received by the 
contralateral breast volume.  
 
III. PLAN COMPARISON DVH 
In addition, to the specific volume and dose comparison for the 
target and OARs, the plan comparison DVH which shows the entire 
isodose distribution of all the structures in the FB and DIBH 
treatment plans were analyzed for all the patients.  
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4.6 SAMPLE SIZE 
 Based on the data reported by Bruzzaniti et al (2013) the mean 
(range) of dose received by the lung in the deep inspirational breath hold 
was 4.64 (3.32-6.11), that is with the SD (standard deviation) of nearly 0.75 
units (76). The same in the free breathing method was 5.51 (3.54-8.84), that 
is with the SD of nearly 1.25 units. In order to show the difference of nearly 
0.9 unit that was statistically significant with alpha and beta errors at 5% 
and 20% respectively, the sample size needed was nearly 19 subjects (who 
will go through both methods). 
 
4.7 STATISTICAL ANALYSIS 
 To compare the dosimetric parameters of the two samples (FB and 
DIBH) which can be paired with one another, the population mean (true 
mean of entire data) was used. Since our study involved comparison of two 
different planning techniques and same sets of measurements in the same 
subjects, a paired t-test statistical analysis was performed. (e.g. target 
coverage, Lung dose, heart dose and LAD doses determined from FB plan 
and DIBH plan with same treatment technique were compared).  
 Suppose a sample of n number of patients were planned on FB 
image sets, the same plan was then created in the DIBH images of the same 
patients to compare the dosimetric characteristics. 
'x' is the dosimetric parameter determined from the FB plan 
'y' is the dosimetric parameter determined from the DIBH plan  
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 To study the null hypothesis that the actual mean difference is zero, 
the following steps are involved: 
1.  Calculate the actual difference between all the paired dosimetric 
parameters of FB and DIBH including positive and negative differences as 
stated below, 
     di = yi − xi 
 
2. Calculate the mean difference, d’ 
3. Calculate the standard deviation (SD) of d'  
4. Calculate the standard error (SE) of d' using following formula,  
   SE (d') = Sd / n 
5. Calculate the t-statistics,  
    T = d' / SE (d') 
 This statistic follows a t-distribution with n − 1 degrees of freedom 
under the null hypothesis 
6. From the tables of t-distribution we compare our values for ‘T’ to the 
tn−1 distribution. 
7. The above distribution gives the p-value (statistical significance) from 
the paired t-test. 
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5. RESULTS 
 
 In our study, single isocenteric Field in Field (FiF) forward IMRT 
conformal radiotherapy plans were generated using Eclipse TPS and the 
dosimetric parameters stated in the methodology (chapter 4) for target and 
OARs were analyzed.  
 
 
5.1 PATIENT CHARACTERISTICS 
 In this study 19 patients were recruited and underwent the CT scan 
as per the study protocol, the mean age being 50 years (ranging from 33 to 
72). Ten out of the nineteen patients had a BMI of more than 25 and the 
mean BMI was found to be 26 (ranging from 17.29 to 34.29). The patients 
were arbitrarily categorized into three age groups  <40 years, 41 to 55 years 
and > 55 years to look for correlation between age and performance 
capacity in general. However, they were not categorised while comparing 
the dosimetric parameters in statistical analysis used in the study. Table 4 
shows the detailed characteristics of the patients in our study. 
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Table 4 Patient characteristics 
 
 
 
 
Patient 
ID 
Hospital Number Age 
Weight 
(kg)  
Height 
(cm) 
BMI 
1 794671F 54 47 157 19.07 
2 844289F 36 52 146 24.39 
3 615537C 48 69 153 29.48 
4 875065F 59 59 145 28.06 
5 849801F 39 79 170 27.34 
6 854345F 49 70 154 29.52 
7 868196F 33 65 155 27.06 
8 011036G 37 66 158 26.44 
9 004575G 63 60 164 22.31 
10 038702G 58 76 167 27.25 
11 150863G 72 62 159 24.52 
12 160167G 41 90 162 34.29 
13 089274G 58 63 156 25.89 
14 035895G 60 52 143 25.43 
15 267728G 38 60 156 24.65 
16 228914G 43 62 165 22.77 
17 142674G 47 62 160 24.22 
18 140744G 44 41 154 17.29 
19 163301G 62 62 155 25.81 
  Mean  50 63 157 26 
 
Minimum  33 41 143 17.29 
  Maximum  72 90 170 34.29 
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5.2 LUNG VOLUMES (Table 5&6) 
 The Primary aim of DIBH is to increase the volume of lung and to 
move the heart away from the chest wall. In our study, we evaluated the 
difference in lung volumes in three age groups and among individual 
patients. The minimum, maximum and mean difference in lung volumes 
(both ipsilateral and combined lung) averaged over each age group is listed 
in table 5. Though the patients in the age group <40 years showed 
considerable difference compared to other two groups in this study, it was 
not statistically significant. The lower values observed in the age group of 
41 to 55 is due to one patient who could not perform the technique and th 
difference of only 40.24 cc was recorded overall for that patient.. Figure 10 
(A) and (B) shows the patient image with poor and good performance 
during the study. The absolute volume of lung (combined and ipsilateral) 
measured for all the patients listed in table 6. There was a significant 
difference in the absolute volume of combined and ipsilateral lung obtained 
with FB and DIBH. 
 
Table 5 The difference in lung volumes in FB and DIBH 
 
Age 
category 
Combined Lung (cc) Ipsilateral Lung (cc) 
Min Max Mean Min Max Mean 
 < 40 1051.2 2177.3 1713.1 709.08 1007.3 874.02 
41 to 55 40.24 1916.7 1285.1 15.11 904.66 621.95 
 > 55 775.49 2196.0 1561.2 319.43 1041.2 744.21 
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Table 6 Absolute volume of lung in FB and DIBH 
Patient 
ID 
Combined Lung volume  
(cc) 
Left Lung Volume (cc) 
FB DIBH Difference FB DIBH Difference 
1 1915.7 3644.4 1728.7 974.2 1867.3 893.1 
2 1803.1 3736.6 1933.6 853.5 1751.3 897.8 
3 1880.6 4057.9 2177.3 903.0 1910.3 1007.3 
4 1718.1 3392.8 1674.7 774.3 1637.1 862.8 
5 2642.0 3693.2 1051.2 1203.0 1912.0 709.1 
6 2047.6 3713.5 1665.9 1015.0 1859.3 844.3 
7 2175.4 3884.9 1709.5 988.1 1814.9 826.8 
8 2312.2 3700.5 1388.3 1004.4 1685.8 681.4 
9 2283.2 3246.2 963.1 1128.1 1584.6 456.6 
10 2718.3 2758.6 40.2 1146.8 1161.9 15.1 
11 1707.8 3020.0 1312.2 752.3 1377.0 624.7 
12 1797.3 3714.0 1916.7 837.6 1742.3 904.7 
13 1868.7 3556.9 1688.2 835.3 1695.8 860.5 
14 2166.8 3693.4 1526.7 903.1 1641.8 738.7 
15 2061.8 3261.6 1199.8 919.8 1524.9 605.1 
16 1357.5 2133.0 775.5 516.3 835.8 319.4 
17 1736.5 3252.9 1516.4 808.2 1518.6 710.4 
18 1924.2 3950.3 2026.1 910.3 1844.6 934.3 
19 1725.5 3921.5 2196.0 724.7 1765.8 1041.2 
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Figure 10 (A) CT image in FB and DIBH (all view) of the patient ID 10 
(poor performance) 
Figure 10 (B) CT images of the patient with good 
performance 
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5.3 DISTANCE OF HEART TO CHEST WALL (Table 7 
& 8) 
 Based on the age groups, the mean distance between the heart and 
CW was analysed at two different levels, one at the centre of the heart in 
FB (taken as reference in this study) to centre of the heart in DIBH and the 
other plane in the DIBH image corresponding to the heart in FB Figure 11 
shows the location of heart at the reference plane in FB and corresponding 
plane on DIBH. 
The mean distances of heart from the CW are demonstrated in figure 12. 
Table 6 shows the minimum, maximum and mean heart distance observed 
in the specified age groups. From this result, the mean difference in the 
distance of the heart from chest wall is considerable in the patients below 
40 years and above 55 years, but no overall correlation has been observed 
between age of the patient and the mean distance. The lesser values 
observed in the age group of 41 to 55 years could be attributed to the poor 
performance of the individuals in this group.  
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Figure 11 Location of heart at the reference plane in FB and 
corresponding plane on DIBH. 
 
  
Figure 12 The mean heart distance from chest wall in FB and DIBH (at 
two planes) 
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Table 7 Distance between of heart to CW in DIBH (in the two planes) 
with respect to FB images  
 
 
 Table 8 Distance between of heart to CW in DIBH (in the two planes) 
with respect to FB images excluding the patient with poor performance 
 
  
5.4 DOSIMETRIC ANALYSIS 
 Various dosimetric parameters were used in our study to compare 
the treatment plans generated in FB and DIBH images of the patients. For 
target volumes, V95, V105, V107 and Dmean were analyzed. Additionally, 
Age 
category 
At center of heart (cm) At reference plane (cm) 
Min Max Mean Min Max Mean 
< 40 0.1 2 1.2 1.2 4 2.4 
41 to 55 0 1.7 0.9 0.1 2.5 1.5 
> 55 0.3 2.7 1.5 0.9 3.7 2.5 
Age 
category 
At center of heart (cm) At reference plane (cm) 
Min Max Mean Min Max Mean 
< 40 0.1 2 1.2 1.2 4 2.4 
41 to 55 0.8 1.7 1.1 1.2 2.5 1.8 
> 55 0.3 2.7 1.5 0.9 3.7 2.5 
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the plan quality indices such as CI and HI were compared as stated above in 
the methods (chapter 4). 
 
A. TARGET COVERAGE (Table 9) 
 In our study, dosimetrically comparable, single isocentered FiF 
forward IMRT plans were generated in FB and DIBH image sets and 
compared. Figure 13 shows the target coverage (95%) in three planes. Table 
9 shows the dosimetric characteristics of FB and DIBH FiF plans. The 
target coverage is comparable which showed 97.8 ±0.9% and 98.1 ±0.8% 
(for V95) for FB FiF and DIBH FiF plan respectively. Further, the high 
dose regions V105, V107 and Dmean showed 6.1 ±3.4%, 0.2 ±0.3% and 
101.9 ±0.5% for FB plans and 6.1 ±3.2%, 0.2 ±0.3% and 101.9 ±0.4% for 
DIBH plans respectively. Hence both the plans were dosimetrically 
identical with target coverage. The p – values were also found to be 
insignificant for all the parameters used. The same is illustrated in figure 14 
which shows the plan comparison (PlanComp) DVH of FB and DIBH plans 
of one of the study patients. In addition, the plan quality indices such as CI 
and HI in FB plans were found to be 1.3 ±0.2 and 0.1 while 1.2 ±0.3 and 
0.1 were recorded in DIBH plans. This substantiates the similarity of 
treatment plans computed  both in FB and DIBH. Figure 11 and 12 shows 
the variation in CI and HI between FB and DIBH plans respectively. 
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Figure 13 Identical target coverage (95%) in FB (left) and DIBH (right) 
in three planes  
 
Table 9 Dosimetric characteristics of target volumes 
Parameter 
FB (%) DIBH (%) P-
Value Min Max Mean SD Min Max Mean SD 
V95 96.1 99.1 97.8 0.9 96.3 99.1 98.1 0.8 0.150 
V105 0.4 11.8 6.1 3.4 0.2 11.1 6.1 3.2 1.000 
V107 0.0 0.9 0.2 0.3 0.0 0.9 0.2 0.3 0.950 
Dmean 100.9 102.8 101.9 0.5 101.1 102.5 101.9 0.4 0.950 
CI 1.0 1.9 1.3 0.2 0.9 2.2 1.2 0.3 0.238 
HI 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.523  
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 Figure 14 PlanComp DVH of FB (triangle) and DIBH (square) 
 
 
Figure 15 Differences in CI between FB and DIBH 
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Figure 16 Differences in HI between FB and DIBH 
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B. LUNG DOSES (Table 10, 11 & 12) 
 The lung volumes (Ipsilateral, Contralateral and Combined) were 
analyzed separately with various dose volume parameters.  
 
 I. IPSILATERAL LUNG (Table 10) 
 The ipsilateral lung volumes were analysed using four different dose 
volume parameters such as V5, V20, V30 and Dmean, among which the V20 
and Dmean are widely used to estimate the radiation induced side effects 
(77,78). Table 10 shows the mean dosimetric characteristics of ipsilateral 
lung for the above parameters. The differences in V5, V20, V30 and Dmean 
are illustrated in figure 17.  
Though, the mean V5 of ipsilateral lung showed only a small 
difference in DIBH with respect to FB, it was found to be statistically 
significant (p value of 0.015). Similarly, the V20 and V 30 along with 
Dmean were also found to be statistically significant (p values of 0.003).  
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Table 10 Dosimetric characteristics of ipsilateral lung volume 
Parameter 
FB (%) DIBH (%) P-
Value Min Max Mean SD Min Max Mean SD 
V5 38.01 56.73 48.82 6.17 34.99 54.2 45.18 5.69 0.015  
V20 16.39 32.21 25.44 4.32 15.97 27.7 21.45 3.42 0.003  
V30 11.02 25.7 20.09 3.75 12.4 22.3 17.72 3.07 0.003  
Dmean 9.42 16.42 13.59 2.05 9.07 15.3 12.13 1.73 -  
      
 
 
(A) 
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Figure 17 Difference in doses received by ipsilateral lung in FB and 
DIBH (A) V5 (B) V20 (C) V30 (D) Dmean 
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II. COMBINED LUNG (Table 11) 
Similarly, for combined lung, the same dosimetric parameters were 
used and reported in table 11. Since, combined lung includes the 
contralateral lung which is not involved in tangential FiF technique, the 
dosimetric parameters were found to be similar with no significant 
difference.  
 
Table 11 Dosimetric characteristics of combined lung volume 
Parameter 
FB (%) DIBH (%) P-
Value Min Max Mean SD Min Max Mean SD 
V5 14.6 26.5 22.26 3.44 15.55 25.2 21.07 3.13 0.100  
V20 6.27 15.5 11.62 2.36 6.6 12.6 10.73 1.78  0.340 
V30 4.2 12.6 9.18 2.02 4.85 10.5 8.25 1.129  0.018 
Dmean 4.1 8.19 6.49 1.12 4.38 7.2 5.91 0.908  0.011 
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(D) 
Figure 18 Difference in doses received by combined lung in FB and 
DIBH (A) V5 (B) V20 (C) V30 (D) Dmean 
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III.  CONTRALATERAL LUNG (Table 12) 
As stated above, the contralateral lung is not involved in tangential 
FiF conformal treatment plan, the parameters V5 (represents low dose 
spread) and Dmean were analysed. Table 12 shows the dose volume report of 
contralateral lung. From above table, it is observed that the dosimetric 
characteristic of FiF plan which contributes very low doses to the 
contralateral lung volume. The p value (0.645) showed statistically 
insignificant difference between the FB and DIBH plans for Dmean. Majority 
of the patients in this study showed 0% volume for V5. Figure 19 shows the 
variation in V5 of contralateral lung. 
 
 
Table 12 Dosimetric characteristics of contralateral lung volume 
Parameter 
FB (%) DIBH (%) P-
Value Min Max Mean SD Min Max Mean SD 
V5 0 0.18 0.025 0.56 0 0.4 0.06 0.11 0.011  
Dmean 0.3 1.01 0.517 0.212 0.28 0.84 0.495 0.16  0.645 
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Figure 19 Variation in V5 of contralateral lung in FB and DIBH 
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C. HEART (Table 13) 
            Heart is one of the main organs at risk while delivering radiotherapy 
to the thoracic region and more so during the treatment of left sided breast 
cancer patients accounting for the long term morbidity and mortality. In 
breast radiotherapy, the V25 and Dmean is most commonly used dose volume 
parameter for evaluating the breast radiotherapy plans. In our study, the FB 
and DIBH plans were evaluated using five different parameters namely, V5, 
V10, V25, V30 and Dmean. Where the V5 (5 Gy volume) corresponds to low 
dose spread to heart in percentage. For better dosimetric evaluation, two 
additional dose volume parameters V10 and V30 were used in our study. 
Table 13 shows the detailed report of the parameters analysed for heart in 
FB and DIBH plans. Figure 20 shows the difference in doses received by 
the heart for all the parameters studied. 
 
Statistical analysis showed that there was significant reduction in 
dose to heart in the DIBH plans for all the parameters that were analysed as 
compared to FB plans (p value of nearly 0.0 for all the parameters). 
According to Quantitative Analysis of Normal Tissue Effects in the Clinic 
(QUANTEC), 2010, the tolerance for heart in conformal radiotherapy to 
breast is V25 ≤ 10% which represents 10% of the heart volume should not 
receive more than 25 Gy. It was observed that V25 of heart was 9.12 
±4.71% in FB FiF plan while the same was as 4.85 ±5.2% in DIBH plan, 
which reduced the V25 almost half with respect to FB plan.  
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Similar results were also found for V30 where the heart volume in 
FB showed 8.43 ±4.48% while DIBH showed 4.71 ±4.57%. Other 
parameters: V5, V10 and Dmean also showed statistically significant results 
(p value of nearly 0.0) for heart volume which clearly supports the DIBH 
technique for left sided breast cancer patients to reduce the radiation 
induced side effects without compromising the target coverage.   
 
 
Table 13 Dosimetric characteristics of Heart 
Parameter 
FB (%) DIBH (%) 
Min Max Mean SD Min Max Mean SD 
V5 9.77 46.7 21.44 9.43 4.18 40.4 15.74 9.15 
V10 4.43 24.15 12.42 5.65 0.5 23.3 7.72 5.98 
V25 2.55 18.3 9.12 4.71 0 18.4 4.85 5.21 
V30 2.22 17.2 8.43 4.48 0 17.4 4.71 4.57 
Dmean 3.1 12.35 6.827 2.69 1.81 12.09 4.775 2.59 
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     (E) 
Figure 20 Difference in doses received by heart in FB and DIBH (A) V5 
(B) V10 (C) V25 (D) V30 and (E) Dmean 
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D. LAD (Table 14) 
 LAD is involved while delivering radiation to the left chest wall as 
the dose is mostly received by the anterior part of the heart where it is 
located. Doses received by the LAD are directly proportional to the risk of 
development of radiation induced ischemic heart disease. Hence in our 
study, LAD doses were evaluated in the FB and DIBH plans with four 
different dose volume parameters (V5, V10, V25 and Dmean). Since the 
volume of LAD is only about 1 cc, delineating and evaluating LAD is a 
difficult task for the physician. Delineation of LAD in our study was 
restricted due to the slice thickness, motion artifacts and the wash out of 
contrast before taking the second set of CT images (DIBH). Table 14 shows 
the LAD dose observed from the FB and DIBH plans. As very few studies 
in the literature dealt with doses to the LAD and no standard protocols for 
estimation of LAD doses and limiting factors or tolerances were defined, 
the parameters used for estimating doses to the heart were used for LAD in 
our study. However, due to its location and considerable variations in its 
delineation according to the physicians expertise, V5 for LAD is unreliable 
and the standard deviation observed in the V5 is an evidence for the same. 
A significant reduction of about 50% in the doses to the LAD in DIBH 
plans was observed in our study in comparison with the FB plans. Further, 
in FB plans, there was lot of fluctuation in the doses to the LAD due to the 
respiratory motion which could be avoided in the DIBH plans. The color 
wash of 95% isodose at level LAD in same plane is illustrated in figure 21. 
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The dose difference between FB and DIBH for all the four parameters were 
significant and are illustrated in figure 22. 
 
 Table 14 Dosimetric Characteristic of LAD 
Parameter 
FB DIBH P-
Value Min Max Mean SD Min Max Mean SD 
V5 14.2 97.56 25.24 53.47 12.51 81.84 41.3 19.81 0.03  
V10 0 86.5 39.52 24.61 0 50 19.94 15.43 0.002  
V25 0 72.48 31.91 24.47 0 45 12.48 15.74 0.002  
Dmean 4 36.94 17.84 10.73 3.06 23.16 9.66 6.454 0.001  
 
   
 
Figure 21 The color wash of 95% isodose at the level of LAD 
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(C) 
 
(D) 
Figure 22 Difference in doses received by LAD in FB and DIBH 
(A) V5 (B) V10 (C) V25 (D) Dmean 
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E. CONTRALATERAL BREAST  
 There is probability of development of second malignancy in the 
contralateral breast due to the scattered dose delivered to contralateral 
breast volume during radiotherapy for breast cancer. In our study, we have 
evaluated three different parameters for contralateral breast which accounts 
for the same. The dose volume characteristic of contralateral breast is listed 
in table 15. Since the dose is mainly contributed from the scattered dose, 
majority of the patients showed no difference in the doses received in FB 
and DIBH, as shown in figure 23. 
 
Table 15 Dosimetric characteristics of contralateral breast  
Parameter 
FB DIBH P-
Value Min Max Mean SD Min Max Mean   
V5 0 4.56 0.44 1.038 0 6.61 0.75 1.698 0.16 
Dmax 3.47 47.59 20.26 10.96 3.46 47.7 18.83 12.35 0.39 
Dmean 0.08 1.47 0.45 0.333 0.2 2.17 0.66 0.48 0.001 
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     (A) 
      (B) 
 
Figure 23 Difference in contralateral doses. V5 (A) and Dmean (B) 
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6 DISCUSSION  
 The advent of combined modality treatment approach in the 
management of breast cancer has led to an improvement in the local control 
and also overall survival, which has led to longer survival and higher 
possibility of late complications  (8,9). Therefore the long term morbidity 
and mortality with radiotherapy has become a concern due to the doses 
received by the organs of risk like heart and lungs resulting in higher 
chances of complication while delivering radiotherapy to the thoracic 
region especially the left side (60). The techniques of radiotherapy have 
improved over the years in an attempt to decrease the doses to the OARS 
and thereby reducing the probability of complications. 
 Radiotherapy (RT) had been shown to be effective in treating breast 
cancer in the early twentieth century. The rationale for postmastectomy 
radiation is prevention of locoregional recurrence (27). Respiratory, cardiac 
and gastrointestinal systems effect the movement of the target during 
radiotherapy, among which respiratory motion has a significant effect on 
the intra and inter fractional treatment delivery. Hence efforts have been 
made to account for and counteract the same of which DIBH technique is 
one of the effective and reproducible methods and widely studied for breast 
cancer treatment (51,64,65).  
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 Our study was performed to evaluate the efficacy of deep 
inspirational breath hold technique and its dosimetric advantages over free 
breathing technique in cardiac (heart and LAD) and ipsilateral lung sparing 
in left-sided postmastectomy FiF conformal radiotherapy. 
 The target coverage parameters (V95, V105, V107 and Dmean) were 
showed insignificant difference in our study. It was found to be 97.8 ±0.9%, 
6.1 ±3.4%, 0.2 ±0.3% and 101.9 ±0.5% respectively in FB plans and 98.1 
±0.8%, 6.1 3.2%, 0.2 ±0.3%, 101.9 ±0.4% in DIBH plans respectively.  In 
addition, the plan quality indices CI and HI were also showed 1.3 ±0.2 and 
0.1 for FB plans. Similar results of 1.2 ±0.3 and 0.1 respectively were also 
found in DIBH plans. Overall, no difference was observed between above 
results.  
 In our study there was significant reduction in dose to heart in the 
DIBH plans compared to FB plans with p value of 0.0 for V5, V10, V25, 
V30 and Dmean dosimetric parameters. There was a 46% reduction in heart 
dose for V25 compared to the FB plan and reduction in Dmean in DIBH as 
compared to FB was 2.05  and the Dmean in DIBH was 4.78 ±2.6 Gy 
which was similar (5.3 ±3 Gy) to that seen in the study reported by Swamy 
et al. . But the data reported by Bruzzaniti et al showed very less dose for 
Dmean (1.2 Gy) for eight patients.  Nissen et al also reported lower Dmean 
doses of 2.7 Gy but their study analysed the doses for DIBH and FB plans 
in two separate groups of patients.  The dose reported for V30 Gy in the 
study by Swamy et al (3.3 ±7.2%) was similar to our results (4.7 ±4.6%). 
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 The ipsilateral lung dose difference between FB and DIBH showed 
statistically significant p values forV5, V20, V30 and Dmean (0.015, 0.00, 
0.003 and 0.00 respectively).  The difference in mean doses between FB 
and DIBH was found to be 7%, 15.7%, 11.8% and 10.7%  in V5, V20, V30 
and Dmean respectively. Further, the results were similar to the results 
reported by swamy et al for ipsilateral lung doses. However, not much 
difference was reported between FB and DIBH and it was found to be 
insignificant (p value of 0.645) as reported in table 12 with minimum 
difference of 4.25% overall.  
 
 In our study there was significant reduction in dose to LAD in the 
DIBH plans compared to FB plans with p value of 0.0 for V5, V10, V25 
and Dmean dosimetric parameters. There was 45.85 % reduction in heart 
dose for V25 compared to the FB plan and reduction in Dmean in DIBH as 
compared to FB was 8.18 Gy and the Dmean in DIBH was 9.66 ±2.6 Gy 
which was similar (5.3 ±3 Gy) to that seen in the study reported by 
Bruzzanaiti et al. 
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7 CONCLUSIONS 
 Deep inspirational breath hold technique (DIBH) resulted in 
significant reduction in doses to the Heart, LAD and Lungs (OARs) as with 
this technique there was an increase in distance between target and the 
OARs. With DIBH there was no compromise in doses to the target volume 
(PTV) with respect to coverage with no under dosage or unacceptable high 
doses. Radiotherapy to chest wall with the DIBH technique therefore 
appears to be superior to FB technique. With appropriate patient selection 
and adequate training, DIBH technique for radiotherapy to the chest is 
acceptable and achievable and therefore should be considered for all 
suitable patients as this could result in less radiotherapy related 
complications. 
 However this technique is time consuming as the set up is complex, 
results in increased time for treatment delivery, needs patient co-operation 
and technical expertise. 
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